Micron (MU) says it plans to construct new fabrication facilities and/or ramp production at existing fabrication facilities to increase supply in to respond to a significant increase in demand for memory products
Every headline is on the live feed 20 minutes before this site.
Canadian Participation Rate (Sep) 64.8% (Prev. 65.0%)
US BROKER MOVES: CBOE upgraded at Morgan Stanley; DD downgraded at JPM
Micron (MU) says it plans to construct new fabrication facilities and/or ramp production at existing fabrication facilities to increase supply in to respond to a significant increase in demand for memory products
Spanish Treasury announces plans to sell 2029, 2031 and 2033 bonds on October 15th
US PRE-MARKET MOVERS: AAPL, SPCX, DAL, HUM/ALHC, LITE
On the Newsquawk feed at , 20 minutes before this page.
- Says competitors may increase capex.
Context
Language of this kind, typically embedded in a filing or call alongside results, is the classic late upcycle tell in memory: the supplier confirms demand is running ahead of supply while simultaneously flagging the capex response that historically plants the seed of the next downturn. The case worth drawing is between DRAM and NAND: tightness driven by AI-linked high bandwidth memory has in past episodes been more durable because of longer qualification and yield ramp timelines, while commodity capacity additions elsewhere in the stack have tended to compress pricing within a few quarters of coming online. The acknowledgement that competitors may raise capex is itself a pattern repeated across prior cycles, where parallel expansion by the three major producers turned shortage into glut; the tell is whether this is disciplined bit-supply growth or a share war. Contract pricing, spot-versus-contract spreads, and peer capex guidance at the next round of results are the follow-ons that separate the two. Equity reaction to such disclosures has historically been two-sided: supportive near term on confirmed demand, a headwind to the group's multiple once the supply response is under way.
Related headlines
- GlobalFoundries (GFS) unveils FDX Fusion FD-SOI platform for physical AI1 hour ago
- Nvidia (NVDA) plans to invest in chip competitor d-Matrix, according to The Information14 hours ago
- TREASURY WRAP: T-NOTE FUTURES (Z6) SETTLE 7+ TICKS HIGHER AT 104-2318 hours ago
- US BROKER MOVES: CBOE upgraded at Morgan Stanley; DD downgraded at JPM1 hour ago
- US PRE-MARKET MOVERS: AAPL, SPCX, DAL, HUM/ALHC, LITE1 hour ago
- Netflix (NFLX) restructuring to impact roughly 5% employees and could be announces as early as next week, Puck reports citing sources2 hours ago
- China's CPCA says Tesla (TSLA) sold 95,366 Chinese-made vehicles in September4 hours ago
- Apple (AAPL) has reportedly told suppliers to cut production of components for its iPhone 18 and Pro Max as rising prices dampens consumer demand, Nikkei reports7 hours ago
- Apple (AAPL) product launch scheduled around Tuesday, October 27th; to debut touch-screen Mac and iPad Mini in late October17 hours ago
- Starbucks (SBUX) says it is 'laser-focused' on existing strategy following Chipotle (CMG) deal chatter, WSJ reports18 hours ago
- US lawmakers show concern over Google's (GOOGL) plan to acquire employee data from Spirit Airlines to train AI models, according to a letter18 hours ago
- TD Cowen see low odds for reported Starbucks (SBUX)-Chipotle (CMG) deal19 hours ago
- Disney (DIS) pitches Paramount (SKYD) and Universal (CMCSA) on a big-screen to compete with Imax (IMAX)19 hours ago
- Synopsys (SNPS) reportedly looking to work with Chinese AI labs to speed up chip design, reports Nikkei19 hours ago
- Delta (DAL) CEO says it was a challenging quarter due to 60% rise in fuel costs, but maintained overall profitability; prices will rise further in Q42 hours ago
- Johnson & Johnson (JNJ) says 2-year ICOTYDE data in moderate-to-severe plaque psoriasis showed sustained efficacy through week 1122 hours ago
- AT&T (T) offers up to USD 1,200 off iPhone duo with eligible trade-in2 hours ago
- Eli Lilly (LLY) announces new exploratory data from the TOGETHER-PsO Phase 3b clinical trial evaluating the concomitant use of Taltz and Zepbound in adults with Psoriasis and Obesity3 hours ago
- Delta Air Lines Inc. (DAL) Q3 2026 (USD): EPS 1.72 (exp. 1.76), Revenue 20.2bln (exp. 18.92bln). Current FY EPS 5.10-5.60 (exp. 5.43)3 hours ago
- Humana (HUM) affirms FY26 adj. EPS guidance of at least USD 9.003 hours ago
The feed had this first.
Use the Platform